Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: satish kamat who wrote (611)	9/21/2000 8:26:07 AM
From: Russian Bear	Respond to of 666

biz.yahoo.com Coulter Pharmaceutical Acquires Rights to Potent Anti-Cancer Compounds SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Sept. 21, 2000-- Coulter Pharmaceutical, Inc. (Nasdaq:CLTR - news) today announced that it has acquired rights to a class of ultra-potent anti-cancer compounds from Kyowa Hakko Kogyo Co., Ltd. of Japan. Coulter intends to enhance the potency of these agents by incorporating them into Coulter's proprietary tumor activated prodrug (TAP) and tumor specific targeting (TST) technologies. The resulting drug candidates will be designed to target the potent anti-cancer power of these agents directly to tumor cells to maximize efficacy while minimizing side-effects to normal tissues. The ultra-potent compounds, Duocarmycin B2 and KW-2189, have been shown to be 1,000 times more potent than standard chemotherapy drugs and work by directly attacking the DNA of cancer cells, causing cell death. <snip>

To: satish kamat who wrote (611)	9/29/2000 1:57:25 PM
From: Howard Bennett	Read Replies (1) \| Respond to of 666

Is this bad? thestreet.com The bad news never seems to end for Immunomedics (IMMU:Nasdaq - news). The biotech company's shares tumbled nearly 6% Tuesday after the Food and Drug Administration accused a testing facility the company has worked with, the Garden State Cancer Center, of testing experimental radioactive drugs on some 72 patients without FDA permission. The agency also charged the center with a litany of other violations of FDA drug-testing rules, including billing patients for experimental drugs without FDA approval.